Diamond Therapeutics Inc. has identified deuterated lisuride analogues acting as 5-HT2A receptor agonists reported to be useful for the treatment of neurological disorders.
Cgenetech (Suzhou, China) Co. Ltd. has described glucagon-like peptide 1 (GLP-1) receptor agonists reported to be useful for the treatment of diabetes.
Researchers at Mossakowski Medical Research Centre at the Polish Academy of Sciences (PAS) and The University of Warsaw have divulged peptides reported to be useful for the treatment of pain.
Impact Therapeutics (Shanghai) Inc. has identified substituted triazoloheteroaryl compounds acting as ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors reported to be useful for the treatment of cancer.
Monte Rosa Therapeutics Inc. has synthesized molecular glue degraders acting as eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1) and cereblon (CRBN) interaction inducers for GSPT1 degradation reported to be useful for the treatment of cancer.
Shanghai Meiyue Biotech Development Co. Ltd. has disclosed serine/threonine-protein kinase SIK2 (QIK) inhibitors reported to be useful for the treatment of metabolic, autoimmune diseases, cardiovascular, dermatological, endocrine disorders, transplant rejection, fibrosis and inflammatory disorders.
Haisco Pharmaceutical Group Co. Ltd. has described proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase cereblon binding moiety covalently coupled to poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) targeting moiety through a linker acting as PARP-1 degradation inducers reported to be useful for the treatment of cancer.
RSS